Hrt Financial LP Neu Base Therapeutics, Inc. Transaction History

Hrt Financial LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.18 - $0.3 $2,804 - $4,674	15,581 New	15,581 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $70,345 - $113,094	-27,056 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $32,493 - $47,300	-9,937 Reduced 26.86%	27,056 $97,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $171,277 - $271,528	36,993 New	36,993 $177,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.